Notice: 函数 WP_Styles::add 的调用方法不正确。 The style with the handle "storefront-woocommerce-style" was enqueued with dependencies that are not registered: storefront-style. 请查阅调试 WordPress来获取更多信息。 (这个消息是在 6.9.1 版本添加的。) in /wordpress/wp-includes/functions.php on line 6260

KB-1606

MK3475-hIgG1

Home » Antibodies » MK3475-hIgG1

Background of MK3475-hIgG1

Pembrolizumab is a humanized monoclonal antibody therapy that targets the cell surface receptor PD-1. It is an immune checkpoint inhibitor initially approved in 2015 for treating metastatic non-small cell lung cancer (NSCLC). Pembrolizumab is an approved first-line therapy for unresectable metastatic melanoma that is often continued beyond complete response despite the fact that immune-related toxicities gradually increase with continuation of therapy.

Specifications

Catalog Number:
KB-1606
Antibody Name:
MK3475-hIgG1
Isotype:
Human IgG1,kappa
FC Muations:
Target:
PD1
Species Reactivity:
Human
Host Cell Line:
EXPI CHO
Purification Method:
Affinity purified
Concentration:
>2 mg/mL
Formulation:
50 mM sodium citrate,150mM NaCl,pH5.5
Purity:
>95% by SDS-PAGE and SEC-HPLC
Validation:
ELISA
Endotoxin Level:
<0.2 EU/mg as determined by the LAL method
Sterility:
0.2μm filtered
Storage:
It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability:
Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

  1. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non–small-cell lung cancer. N Engl J Med 2015;372:2018-2028.
  2. Chatterjee M, Turner DC, Felip E, et al. Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer. Ann Oncol 2016;27:1291-1298.